

STAR team member Follow Up (phone or inperson) within 3 days of first visit

- Check on how first dose went
- Assess issues obtaining medication
- Ensure participant is letting the film melt entirely under tongue
- Assess for side effects: If so- speak with a STAR provider, and remind participant to call/text with any concerns
- Reminder call/text the day before follow up appointment

Participant is Not Interested or appropriate (current/recent opioid use or LFTs >5 times normal range)

Confirm participant has naloxone; if not- training and kit **Assist with outside referral (call to help set up visit and any other assistance needed)

Follow Up Visits

- Participant meets with STAR BH provider for brief check-in
 - o STAR team member obtains urine and puts POC urine results into note
- MA checks urine pregnancy test as applicable (monthly for women with a uterus who have not undergone sterilization)
- Provider visit- check PMP, review STAR BH note (see STAR manual for more information and quick texts)
 - 0 Order LFTs, HIV and HCV every 6 months
 - 0 LFTs monitored every 1-2 months for elevation >2 times upper limit of normal

Suggested Follow up Visit Frequency (duration between visits extends as stability increases):

- Visits at least weekly for first month
- If consistently positive for bup, expected bup:norbup ratio, and no other opioid use, can increase visits to every 2 weeks for one month
- If consistently positive for bup, expected bup:norbup ratio, and no other opioid use, extend visits to every 3-4 weeks

Buprenorphine use with no illicit use

- Monthly visits with provider
- Monthly STAR BH visits and more as needed
- Visits may be extended to every 2 months on a case by case basis, taking social circumstances and duration of stability into account

Buprenorphine use with illicit use

- Weekly visits with provider & STAR team member
- Offer higher level of support (i.e. referral to residential, IOP, or OP; increased NA/AA; or increased check-ins with HAH STAR team member)
- Offer harm reduction education and ensure has naloxone

No or Intermittent Buprenorphine use with other opioid use

- Offer higher level of care (i.e. referral to residential, IOP, or OP; increased NA/AA; or increased check-ins with HAH STAR team member)
- Let them know if continually negative for buprenorphine, we can no longer prescribe
- Case discussion with MAT Director and full STAR team
- Offer harm reduction education
 and ensure has naloxone